CAS 1844064 96 5 Velpatasvir Intermediates Velpatasvir Co Povidone / Povidona GMP powder

CAS : 1844064-96-5 Velpatasvir Intermediates Velpatasvir Co Povidone / Povidona

Chemical Name : Methyl N - ( ( ( 2S , 5S ) - 2 - ( 17 - ( 17 - ( 2 - ( ( 2S , 4S ) - 4 - ( methoxymethyl ) pyrrolidin - 2 - yl ) - 1H - imidazol - 5 - yl ) - 21 - oxa - 5 , 7 - diazapentacyclo ( 11 . 8 . 0 . 0 ³ , ¹¹ . 0 ⁴ , ⁸ . 0 ¹⁴ , ¹⁹ ) henicosa - 1 , 3 ( 11 ) , 4 ( 8 ) , 6 , 9 , 12 , 14 , 16 , 18 - nonaen - 6 - yl ) - 5 - methylpyrrolidin - 1 - yl ) - 3 - methyl - 1 - oxobutan - 2 - yl ) carbamate

CAS No. : 1844064-96-5

Molecular Formula : C39H45N7O5

Molecular Weight : 691.83

Usage : Velpatasvir Intermediate

Description :

Velpatasvir is innovated by Gilead to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Velpatasvir is a Direct-Acting Antiviral (DAA) medication used together with Sofosbuvir. The mechanism of action is as a Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Organic Anion Transporting Polypeptide 2B1 Inhibitor. It blocks NS5A, a protein necessary for hepatitis C virus replication assembly.

Velpatasvir Co Povidone / Povidona CAS No . : 1844064-96-5 is an advanced intermediate of velpatasvir. There might be several synthesis routes to manufacture this intermediate but some routes or compounds are protected by the patents in some countries and regions. We strictly obey the laws and our products will not be sold to those areas protected by patents for commercial purposes. Anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.

Asambly is foucing on R&D, scale up, manufacturing of Active Pharmaceutical Ingredients (APIs) incluidng their intermediates. All the production is complied with the cGMP standard.